Document is current
Any future updates will be listed below
-
Authors
Endres, Dominique http://orcid.org/0000-0001-7322-1195
Pankratz, Benjamin
Robinson, Tilman
Pitsch, Karoline
Göbel, Theresa
Runge, Kimon http://orcid.org/0000-0002-0263-4360
Schlump, Andrea
Nickel, Kathrin
Reisert, Marco
Urbach, Horst
Voderholzer, Ulrich
Venhoff, Nils
Domschke, Katharina http://orcid.org/0000-0002-2550-9132
Prüss, Harald http://orcid.org/0000-0002-8283-7976
Schiele, Miriam A.
Tebartz van Elst, Ludger http://orcid.org/0000-0002-2274-5447
- License Information
-
More Information
Article History
Received: 12 February 2022
Revised: 25 June 2022
Accepted: 27 June 2022
First Online: 13 July 2022
Competing interests
: HU: Shareholder of the Veobrain. KD: Steering Committee Neurosciences, Janssen. LTvE: Advisory boards, lectures, or travel grants within the last 3 years: Roche, Eli Lilly, Janssen-Cilag, Novartis, Shire, UCB, GSK, Servier, Janssen and Cyberonics. All other authors declare no potential competing interests.
: The patient has given her signed written informed consent for this case report to be published.
